COMMUNIQUÉS West-GlobeNewswire

Ipsen announces the launch of an Employee Shareholding Plan
29/05/2026
Ipsen announces the launch of an employee shareholding plan PARIS, FRANCE, 29 MAY 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today the launch of an employee shareholding plan. This fifth transaction in the last [...]
ALK to present at the Jefferies Global Healthcare Conference in New York
29/05/2026
ALK (ALKB:DC / Nasdaq Copenhagen: ALK B) today announced that the company’s Executive Vice President and CFO, Claus Steensen Sølje, is scheduled to present at the 2026 Jefferies Global Healthcare Conference in New York [...]
MannKind Announces FDA Approval of Afrezza®, the First and Only Inhaled Mealtime Insulin for Use in Children and Adolescents Aged 6 and Older Living with Diabetes
29/05/2026
Enables dosing at the start of a meal, offering flexibility for children and adolescents as they manage school, sports, meals, and snacks throughout the day Approval advances pediatric diabetes care by introducing a new [...]
Ipsen annonce le lancement d'une opération d’actionnariat salarié
29/05/2026
Ipsen annonce le lancement d'une opération d’actionnariat salarié PARIS, FRANCE, 29 MAI 2026 - Ipsen (Euronext : IPN ; ADR : IPSEY), annonce aujourd’hui le lancement d'une opération d’actionnariat salarié. Cette 5 ème [...]
Cuprina Holdings Announces Completion of Reverse Stock Split and Requests a Hearing before the Nasdaq Hearings Panel to Maintain Listing
29/05/2026
SINGAPORE, May 29, 2026 (GLOBE NEWSWIRE) -- Cuprina Holdings ( Cayman ) Limited ( Nasdaq: CUPR ) (“ Cuprina ” or “ the Company ”), a biomedical company developing and marketing products for the chronic wounds, [...]
Jyong Biotech CEO Outlines FDA Pathway and Global Strategy in PharmaBoardroom Live Interview
29/05/2026
New Taipei City, Taiwan, May 29, 2026 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”), a science-driven biotechnology company dedicated to the development and commercialization [...]
At ASCO and EHA 2026, New Data Reinforce the Pivotal Role of clonoSEQ® MRD Testing Across Hematology Clinical Practice and Research
29/05/2026
Over 30 scientific presentations leverage clonoSEQ MRD testing to assess novel therapies and support MRD-guided patient care across blood cancers SEATTLE, May 29, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies [...]
Glass House Brands Completes Previously Announced Warrant Redemption
29/05/2026
LONG BEACH, Calif. and TORONTO, May 29, 2026 (GLOBE NEWSWIRE) -- Glass House Brands Inc. ("Glass House" or the “Company”) (CBOE CA: GLAS.A.U) (CBOE CA: GLAS.WT.U) (OTCQX: GLASF) (OTCQX: GHBWF) today announced the [...]
Rhythm Pharmaceuticals Announces Seven Abstracts Accepted for Presentation at ENDO 2026
29/05/2026
BOSTON, May 29, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine [...]
Bioxytran Highlights New Book on Real-Time Monitoring Tissue Oxygenation Relevant to Oxygen Carrier BXT-25
29/05/2026
Brain tissue oxygenation in early stage of stroke with BXT-25 is monitored in real time BOSTON, MASSACHUSETTS, May 29, 2026 (GLOBE NEWSWIRE) -- Bioxytran Inc. (OTCQB: BIXT), a biotechnology company developing [...]
Tenaya Therapeutics to Participate in the Jefferies Global Healthcare Conference 2026
29/05/2026
SOUTH SAN FRANCISCO, Calif., May 29, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative [...]
Omniscient Secures USD 27.2M Series D to Accelerate Commercialization of AI-Enabled Brain Technology
29/05/2026
Funding to scale FDA-cleared Quicktome® platform and drive next-generation personalized brain care globally SAN FRANCISCO, May 29, 2026 (GLOBE NEWSWIRE) -- Omniscient (o8t®), a pioneer in AI-driven brain analysis [...]
SAB BIO to Present Data on SAB-142 at The American Diabetes Association’s 2026 Scientific Sessions and FOCIS 2026 Annual Meeting
29/05/2026
Data will highlight deeper mechanistic insights and long-term dosing potential of SAB-142, a fully human multi-specific ATG for newly diagnosed Stage 3 T1D MIAMI, May 29, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, [...]
PetMed Express, Inc. to Report Fourth Quarter and Fiscal Year 2026 Financial Results on Tuesday, June 2, 2026
29/05/2026
DELRAY BEACH, Fla., May 29, 2026 (GLOBE NEWSWIRE) -- PetMed Express, Inc., dba PetMeds and parent company of PetCareRx, (Nasdaq: PETS) today announced it will report financial results for the fourth quarter and fiscal [...]
Clearmind Medicine Advances Global Intellectual Property Portfolio with Japanese Patent Filing for Innovative Psychedelic- Based Depression Treatment
29/05/2026
Vancouver, Canada, May 29, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non- [...]
Dr. Kamalesh Sets New Benchmarks for Urological Surgery in the UAE: Minimally Invasive, Maximum Results!
29/05/2026
DUBAI, United Arab Emirates, May 29, 2026 (GLOBE NEWSWIRE) -- Recognized as one of the best urologists in Dubai , Dr. Kamalesh is raising the standard for patient care as the UAE enters the hotter summer months, a [...]
Moleculin Presents ASCO 2026 Data Demonstrating No Detectable Cardiotoxicity with Annamycin Despite Exposure Levels Far Exceeding Conventional Anthracycline Limits
29/05/2026
Independent Cleveland Clinic Cardiac Review Supports Potential Best-in-Class Safety Profile as MIRACLE Phase 2b/3 Trial Advances HOUSTON, May 29, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) (“ [...]
Aptose Biosciences Announces Update on Anticipated Timing of Closing of the Plan of Arrangement with Hanmi Pharmaceutical
29/05/2026
SAN DIEGO and TORONTO, May 29, 2026 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“ Aptose ” or the “ Company ”) (TSX: APS; OTC: APTOF) announced today that closing of the previously announced arrangement (the “ [...]
Replimune Announces Planned RP1 BLA Resubmission Following Productive Discussion with FDA
29/05/2026
WOBURN, Mass., May 29, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that following [...]

Pages